Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-10-01

FDA Approved: SOGROYA — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved a supplemental application for SOGROYA (somapacitan) from Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sogroya (somapacitan)

Snippet

SUPPL AP for SOGROYA (SOMAPACITAN-BECO)